{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:21:00Z","timestamp":1740144060813,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T00:00:00Z","timestamp":1688774400000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s40261-023-01279-2","type":"journal-article","created":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T17:01:16Z","timestamp":1688835676000},"page":"529-540","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Estimating the Product Lifecycle Value of Trastuzumab Based on Registry Data in Sweden"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7981-7299","authenticated-orcid":false,"given":"Nahila","family":"Justo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nils","family":"Wilking","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linus","family":"J\u00f6nsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,8]]},"reference":[{"issue":"2","key":"1279_CR1","first-page":"515","volume":"73","author":"D Vandegrift","year":"2006","unstructured":"Vandegrift D, Datta A. Prescription drug expenditures in the united states: the effects of obesity, demographics, and new pharmaceutical products. South Econ J. 2006;73(2):515\u201329.","journal-title":"South Econ J"},{"key":"1279_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40545-015-0046-2","volume":"8","author":"A Vitry","year":"2015","unstructured":"Vitry A, Nguyen T, Entwistle V, Roughead E. Regulatory withdrawal of medicines marketed with uncertain benefits: the bevacizumab case study. J Pharm Policy Pract. 2015;8:25.","journal-title":"J Pharm Policy Pract."},{"issue":"8","key":"1279_CR3","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1093\/annonc\/mdx110","volume":"28","author":"A Aggarwal","year":"2017","unstructured":"Aggarwal A, Fojo T, Chamberlain C, Davis C, Sullivan R. Do patient access schemes for high-cost cancer drugs deliver value to society?-lessons from the NHS Cancer Drugs Fund. Ann Oncol. 2017;28(8):1738\u201350.","journal-title":"Ann Oncol"},{"issue":"Suppl 4","key":"1279_CR4","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1097\/00001813-200112004-00002","volume":"12","author":"IE Smith","year":"2001","unstructured":"Smith IE. Efficacy and safety of Herceptin in women with metastatic breast cancer: results from pivotal clinical studies. Anticancer Drugs. 2001;12(Suppl 4):S3-10.","journal-title":"Anticancer Drugs"},{"key":"1279_CR5","doi-asserted-by":"crossref","unstructured":"Eiermann W, International Herceptin Study G. Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data. Ann Oncol. 2001;12:S57-62.","DOI":"10.1093\/annonc\/12.suppl_1.S57"},{"issue":"19","key":"1279_CR6","doi-asserted-by":"publisher","first-page":"4265","DOI":"10.1200\/JCO.2005.04.173","volume":"23","author":"M Marty","year":"2005","unstructured":"Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005;23(19):4265\u201374.","journal-title":"J Clin Oncol"},{"issue":"14","key":"1279_CR7","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"D Slamon","year":"2011","unstructured":"Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273\u201383.","journal-title":"N Engl J Med"},{"issue":"12","key":"1279_CR8","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1200\/JCO.2005.02.8886","volume":"24","author":"J Hurley","year":"2006","unstructured":"Hurley J, Doliny P, Reis I, et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol. 2006;24(12):1831\u20138.","journal-title":"J Clin Oncol"},{"issue":"16","key":"1279_CR9","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673\u201384.","journal-title":"N Engl J Med"},{"key":"1279_CR10","unstructured":"Early Breast Cancer Trialists' Collaborative group (EBCTCG). Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. Lancet Oncol. 2021;22(8):1139-1150."},{"issue":"8","key":"1279_CR11","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1111\/j.1524-4733.2009.00572.x","volume":"12","author":"LP Garrison Jr","year":"2009","unstructured":"Garrison LP Jr, Veenstra DL. The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer. Value Health. 2009;12(8):1118\u201323.","journal-title":"Value Health."},{"key":"1279_CR12","unstructured":"Adam Lundqvist NW, Ulf-G Gerdtham, Ulf Persson, Katarina Steen Carlsson. M\u00e5lriktad behandling av br\u00f6stcancer Stockholm, Sweden: SNS;2013."},{"key":"1279_CR13","unstructured":"Statistics Sweden. Mortality statistics published by SCB. https:\/\/www.statistikdatabasen.scb.se\/pxweb\/sv\/ssd\/START__BE__BE0101__BE0101I\/DodaFodelsearK\/. Accessed 1 Nov 2022."},{"issue":"2","key":"1279_CR14","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1017\/S0266462307070328","volume":"23","author":"M Lidgren","year":"2007","unstructured":"Lidgren M, Wilking N, Jonsson B, Rehnberg C. Resource use and costs associated with different states of breast cancer. Int J Technol Assess Health Care. 2007;23(2):223\u201331.","journal-title":"Int J Technol Assess Health Care"},{"key":"1279_CR15","unstructured":"Sveriges Kommuner och Regioner. Healthcare price index (V\u00e5rdprisindex-VPI). https:\/\/skr.se\/skr\/ekonomijuridik\/ekonomi\/budgetochplanering\/prisindex\/vpi.31954.html. Accessed 8 Mar 2022."},{"key":"1279_CR16","unstructured":"E-h\u00e4lsomyndigheten. Drug Sales Statistics (F\u00f6rs\u00e4ljningsstatistiken). https:\/\/www.ehalsomyndigheten.se\/statistik-och-lakemedelsforsaljning\/bestalla-statistik\/. Accessed 8 Mar 2022."},{"key":"1279_CR17","unstructured":"Statistics Sweden. Consumer price index (KPI). https:\/\/www.statistikdatabasen.scb.se\/pxweb\/sv\/ssd\/START__PR__PR0101__PR0101A\/. Accessed 8 Mar 2022."},{"key":"1279_CR18","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.breast.2016.07.008","volume":"29","author":"S Olofsson","year":"2016","unstructured":"Olofsson S, Norrlid H, Karlsson E, Wilking U, Ragnarson TG. Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer\u2014An observational study prospectively recording resource utilization in a Swedish healthcare setting. Breast. 2016;29:140\u20136.","journal-title":"Breast"},{"issue":"6","key":"1279_CR19","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s11136-007-9202-8","volume":"16","author":"M Lidgren","year":"2007","unstructured":"Lidgren M, Wilking N, Jonsson B, Rehnberg C. Health related quality of life in different states of breast cancer. Qual Life Res. 2007;16(6):1073\u201381.","journal-title":"Qual Life Res"},{"key":"1279_CR20","doi-asserted-by":"crossref","unstructured":"Balduzzi S, Mantarro S, Guarneri V, et al. Trastuzumab-containing regimens for metastatic breast cancer. Cochrane Database of Systematic Rev. 2014;2014(6) (no pagination).","DOI":"10.1002\/14651858.CD006242.pub2"},{"key":"1279_CR21","first-page":"5","volume":"2","author":"L Hultkrantz","year":"2008","unstructured":"Hultkrantz L, Svensson M. V\u00e4rdet av liv. Ekonomisk debatt. 2008;2:5\u201316.","journal-title":"Ekonomisk debatt."},{"issue":"2","key":"1279_CR22","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1080\/13571516.2011.584428","volume":"18","author":"JP Cook","year":"2011","unstructured":"Cook JP, Golec JH, Vernon JA, Pink GH. Real option value and path dependence in oncology innovation. Int J Econ Bus. 2011;18(2):225\u201338.","journal-title":"Int J Econ Bus"},{"issue":"7","key":"1279_CR23","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1002\/hec.3899","volume":"28","author":"M Li","year":"2019","unstructured":"Li M, Basu A, Bennette CS, Veenstra DL, Garrison LP. Do cancer treatments have option value? Real-world evidence from metastatic melanoma. Health Econ. 2019;28(7):855\u201367.","journal-title":"Health Econ"},{"issue":"10","key":"1279_CR24","first-page":"1082","volume":"25","author":"LP Garrison","year":"2019","unstructured":"Garrison LP, Towse A. A strategy to support efficient development and use of innovations in personalized medicine and precision medicine. J Manag Care Spec Pharm. 2019;25(10):1082\u20137.","journal-title":"J Manag Care Spec Pharm"},{"key":"1279_CR25","unstructured":"Labour market status by region, sex, age and region of birth. Preliminary statistics. Year 2020\u20132022. Statistics Sweden. https:\/\/www. stati stikd ataba sen. scb. se\/ pxweb\/ en\/ ssd\/ START__ AM__ AM0210__ AM021 0A\/ ArbSt atusAr\/ table\/ table ViewL ayout1\/. Accessed 24 May 2023."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01279-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-023-01279-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01279-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T17:05:39Z","timestamp":1690477539000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-023-01279-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["1279"],"URL":"https:\/\/doi.org\/10.1007\/s40261-023-01279-2","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"type":"print","value":"1173-2563"},{"type":"electronic","value":"1179-1918"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"29 May 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work, and have given final approval to the version to be published. All authors contributed to the conceptualization of the study, data curation, investigation, reviewing and editing of the manuscript. NJ and LJ contributed to the formal analyses, and project administration. LJ designed the methodology and model. NJ wrote the original draft. LJ and NW contributed to the supervision and validation of findings.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}},{"value":"No funding was received to conduct this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The datasets generated and\/or analysed during this study were obtained from the Swedish National Quality Register for Breast Cancer (NKBC) and eH\u00e4lsomyndigheten. Summary data from the former can be found here: . Patient-level data from the former and product-specific sales data from the latter are only available upon application and approval of the study-specific request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Analyses of the individual-patient level data were performed in R, the models were built in Excel","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"The study was approved by the Swedish Ethical Review Authority (Etikpr\u00f6vningsmyndigheten) Dnr 2021-06709-01 and was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Nahila Justo is employed by Evidera, which provides consulting and other research services to pharmaceutical, medical devices, and related organisations. In her salaried position, she works with a variety of companies and organisations, and is precluded from receiving payment or honoraria directly from these organisations for services rendered. The work herein was not conducted as part of her employment. Nils Wilking reports personal fees from AstraZeneca, Bayer, Daichii Sankyo, Incyte, Jansen, MSD, Novartis, Pierre Fabre and Oasmia for participation in advisory boards and educational activities. Linus J\u00f6nsson has no competing interests to declare.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}